Garnering a standing ovation at IAS 2025, Sameer Sah, from Medical Aid for Palestinians, provided a devastating first-hand account of what’s been happening for nearly two years in Gazan healthcare ...

More than half of people who received a pair of broadly neutralising antibodies (bnAbs) plus the immune-modulating drug N-803 (Anktiva) had delayed viral rebound or maintained a low or suppressed ...

New data presented at the 13th International AIDS Society Conference on HIV Science (IAS 2025) yesterday show that two long-acting injectable PrEP options, lenacapavir and cabotegravir, are safe, well ...

One year ago, UNAIDS announced that the HIV response was at a critical crossroads. Apart from a handful of countries, the world was not on track to meet the ambitious 2030 goals: 95% of those ...

Semaglutide and related weight-loss medications, known as GLP-1 agonists, may slow biological ageing, reduce inflammation, improve cognitive function and gut health, and reduce alcohol use in people ...

Two more people appear to be free of HIV after stem cell transplants for cancer treatment, according to a pair of posters presented at the Conference on Retroviruses and Opportunistic Infections (CROI ...

A mutation that can undermine two-drug treatment with dolutegravir and lamivudine persists for at least 12 years in the ‘archive’ of HIV locked up in the DNA of blood cells in one in three people ...

📢 With heavy hearts, we announce the proposed closure of our beloved charity, NAM aidsmap, this month. After 37 years of pioneering health journalism, community engagement, and empowerment through ...

A CRISPR-based gene-editing therapy called EBT-101 was safe and well tolerated but did not prevent viral rebound in three participants who stopped antiretroviral treatment in an early study, according ...

A symposium at the Conference on Retroviruses and Opportunistic Infections (CROI 2024) earlier this month included presentations advocating changes in practice on what might be called opposite ends of ...

HIV pre-exposure prophylaxis (PrEP) could in theory stop the majority of HIV transmissions that still happen, and in some places, including England, is doing so. Yet worldwide, it is still only being ...

Lifetime risk of acquiring HIV has decreased for Black gay and bisexual men in the US, from 1 in 2 from 2010 to 2014 to 1 in 3 from 2017 to 2021, according to data presented to the Conference on ...